The 9 references in paper A. Polyakov P., N. Volchenko N., E. Slavnova N., A. Kudryavtseva V., M. Ratushnyy V., V. Ratushnaya V., M. Filyushin M., I. Rebrikova V., P. Nikiforovich A., А. Поляков П., Н. Волченко Н., Е. Славнова Н., А. Кудрявцева В., М. Ратушный В., В. Ратушная В., М. Филюшин М., И. Ребрикова В., П. Никифорович А. (2017) “ВЛИЯНИЕ СТАТУСА ГЕНА BRAF НА ВЫБОР ТАКТИКИ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ // THE ROLE OF BRAF MUTATION STATUS IN SURGICAL TREATMENT OF WELL-DIFFERENTIATED THYROID CANCER” / spz:neicon:ogsh:y:2016:i:4:p:45-48

1
Hodgson N.C., Button J., Solorzano C. et al. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004;11:1093–7.
(check this in PDF content)
2
Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295(18):2164–7.
(check this in PDF content)
3
Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54.
(check this in PDF content)
4
Xing М. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28(7):742–62.
(check this in PDF content)
5
Fugazzola L., Puxeddu E., Avenia N. et al. Correlation between В-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13(2): 455–64.
(check this in PDF content)
6
Basolo F., Torregrossa L., Giannini R. et al. Сorrelation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. J Clin Endocrinol Metab 2010;95(9):4197–4205. DOI: 10.1210/jc.2010-0337.
(check this in PDF content)
7
Xing M., Westra W.H., Tufano R.P. et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90(12): 6373–9.
(check this in PDF content)
8
Barollo S., Pennelli G., Vianello F. et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 2010;163(4):659–63.
(check this in PDF content)
9
Brose M.S., Schlumberger M., Peña C., Kappeler C. Sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3. Lancet
(check this in PDF content)